Prescription of nCPAP and nBIPAP in obstructive sleep apnoea syndrome: Italian experience in 105 subjects. A prospective two centre study

O. Resta, P. Guido, V. Picca, R. Sabato, M. Rizzi, F. Scarpelli, M. Sergi

Research output: Contribution to journalArticle

Abstract

Nasal continuous positive airway pressure (nCPAP) is the current treatment of obstructive sleep apnoea syndrome (OSAS). The indications of bilevel pressure support ventilation (BIPAP PSV) in OSAS patients remain controversial. The purpose of this investigation was to verify the frequency of prescription of BIPAP PSV in a group of OSAS patients when CPAP was ineffective or not tolerated during titration. The study included 286 consecutive patients ≤ 18 years of age referred to two Sleep laboratories for sleep related breathing disorders (SRBD) between December 1994 and November 1995. Of these, 130 patients were enrolled and 105 (88 males, 77 females) with moderate to severe OSAS completed the study and were finally analysed. After a full night diagnostic polysomnography (PSG(D)), patients had a second full night PSG under nCPAP (PSG(T)). If nCPAP was not tolerated, or failed to correct breathing abnormalities during sleep, a second PSG(T) was performed, using a BIPAP PSV. Our study shows that nCPAP (mean 8.5 ± 2 0 cmH2O) was considered a satisfactory therapy in 81 patients (77%). Twenty four (23%) required BIPAP PSV (mean IPAP 13.9 ± 2.9 cmH2O). We found the highest prevalence of BIPAP in patients with OSAS associated to obesity hypoventilation syndrome (OHS) (11 of 17) and in OSAS associated to chronic obstructive pulmonary disease (COPD) (nine of 16). Patients treated with BIPAP PSV were more obese and had a higher PaCO2, and sleep-related desaturations and a lower FEV1, FVC, FEV1/FVC and PaO2. In conclusion our study shows that CPAP therapy is the effective therapeutic option in the majority of patients with OSAS, There is a subset of patients with OSAS associated to COPD or to OHS in whom BIPAP PSV may be a better treatment modality.

Original languageEnglish
Pages (from-to)820-827
Number of pages8
JournalRespiratory Medicine
Volume92
Issue number6
DOIs
Publication statusPublished - Jun 1998

Fingerprint

Continuous Positive Airway Pressure
Obstructive Sleep Apnea
Prescriptions
Sleep
Obesity Hypoventilation Syndrome
Chronic Obstructive Pulmonary Disease
Respiration
Therapeutics
Polysomnography
Ventilation
Pressure

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Prescription of nCPAP and nBIPAP in obstructive sleep apnoea syndrome : Italian experience in 105 subjects. A prospective two centre study. / Resta, O.; Guido, P.; Picca, V.; Sabato, R.; Rizzi, M.; Scarpelli, F.; Sergi, M.

In: Respiratory Medicine, Vol. 92, No. 6, 06.1998, p. 820-827.

Research output: Contribution to journalArticle

Resta, O. ; Guido, P. ; Picca, V. ; Sabato, R. ; Rizzi, M. ; Scarpelli, F. ; Sergi, M. / Prescription of nCPAP and nBIPAP in obstructive sleep apnoea syndrome : Italian experience in 105 subjects. A prospective two centre study. In: Respiratory Medicine. 1998 ; Vol. 92, No. 6. pp. 820-827.
@article{9e0afded18144d74a80da0c2551dae28,
title = "Prescription of nCPAP and nBIPAP in obstructive sleep apnoea syndrome: Italian experience in 105 subjects. A prospective two centre study",
abstract = "Nasal continuous positive airway pressure (nCPAP) is the current treatment of obstructive sleep apnoea syndrome (OSAS). The indications of bilevel pressure support ventilation (BIPAP PSV) in OSAS patients remain controversial. The purpose of this investigation was to verify the frequency of prescription of BIPAP PSV in a group of OSAS patients when CPAP was ineffective or not tolerated during titration. The study included 286 consecutive patients ≤ 18 years of age referred to two Sleep laboratories for sleep related breathing disorders (SRBD) between December 1994 and November 1995. Of these, 130 patients were enrolled and 105 (88 males, 77 females) with moderate to severe OSAS completed the study and were finally analysed. After a full night diagnostic polysomnography (PSG(D)), patients had a second full night PSG under nCPAP (PSG(T)). If nCPAP was not tolerated, or failed to correct breathing abnormalities during sleep, a second PSG(T) was performed, using a BIPAP PSV. Our study shows that nCPAP (mean 8.5 ± 2 0 cmH2O) was considered a satisfactory therapy in 81 patients (77{\%}). Twenty four (23{\%}) required BIPAP PSV (mean IPAP 13.9 ± 2.9 cmH2O). We found the highest prevalence of BIPAP in patients with OSAS associated to obesity hypoventilation syndrome (OHS) (11 of 17) and in OSAS associated to chronic obstructive pulmonary disease (COPD) (nine of 16). Patients treated with BIPAP PSV were more obese and had a higher PaCO2, and sleep-related desaturations and a lower FEV1, FVC, FEV1/FVC and PaO2. In conclusion our study shows that CPAP therapy is the effective therapeutic option in the majority of patients with OSAS, There is a subset of patients with OSAS associated to COPD or to OHS in whom BIPAP PSV may be a better treatment modality.",
author = "O. Resta and P. Guido and V. Picca and R. Sabato and M. Rizzi and F. Scarpelli and M. Sergi",
year = "1998",
month = "6",
doi = "10.1016/S0954-6111(98)90383-3",
language = "English",
volume = "92",
pages = "820--827",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Prescription of nCPAP and nBIPAP in obstructive sleep apnoea syndrome

T2 - Italian experience in 105 subjects. A prospective two centre study

AU - Resta, O.

AU - Guido, P.

AU - Picca, V.

AU - Sabato, R.

AU - Rizzi, M.

AU - Scarpelli, F.

AU - Sergi, M.

PY - 1998/6

Y1 - 1998/6

N2 - Nasal continuous positive airway pressure (nCPAP) is the current treatment of obstructive sleep apnoea syndrome (OSAS). The indications of bilevel pressure support ventilation (BIPAP PSV) in OSAS patients remain controversial. The purpose of this investigation was to verify the frequency of prescription of BIPAP PSV in a group of OSAS patients when CPAP was ineffective or not tolerated during titration. The study included 286 consecutive patients ≤ 18 years of age referred to two Sleep laboratories for sleep related breathing disorders (SRBD) between December 1994 and November 1995. Of these, 130 patients were enrolled and 105 (88 males, 77 females) with moderate to severe OSAS completed the study and were finally analysed. After a full night diagnostic polysomnography (PSG(D)), patients had a second full night PSG under nCPAP (PSG(T)). If nCPAP was not tolerated, or failed to correct breathing abnormalities during sleep, a second PSG(T) was performed, using a BIPAP PSV. Our study shows that nCPAP (mean 8.5 ± 2 0 cmH2O) was considered a satisfactory therapy in 81 patients (77%). Twenty four (23%) required BIPAP PSV (mean IPAP 13.9 ± 2.9 cmH2O). We found the highest prevalence of BIPAP in patients with OSAS associated to obesity hypoventilation syndrome (OHS) (11 of 17) and in OSAS associated to chronic obstructive pulmonary disease (COPD) (nine of 16). Patients treated with BIPAP PSV were more obese and had a higher PaCO2, and sleep-related desaturations and a lower FEV1, FVC, FEV1/FVC and PaO2. In conclusion our study shows that CPAP therapy is the effective therapeutic option in the majority of patients with OSAS, There is a subset of patients with OSAS associated to COPD or to OHS in whom BIPAP PSV may be a better treatment modality.

AB - Nasal continuous positive airway pressure (nCPAP) is the current treatment of obstructive sleep apnoea syndrome (OSAS). The indications of bilevel pressure support ventilation (BIPAP PSV) in OSAS patients remain controversial. The purpose of this investigation was to verify the frequency of prescription of BIPAP PSV in a group of OSAS patients when CPAP was ineffective or not tolerated during titration. The study included 286 consecutive patients ≤ 18 years of age referred to two Sleep laboratories for sleep related breathing disorders (SRBD) between December 1994 and November 1995. Of these, 130 patients were enrolled and 105 (88 males, 77 females) with moderate to severe OSAS completed the study and were finally analysed. After a full night diagnostic polysomnography (PSG(D)), patients had a second full night PSG under nCPAP (PSG(T)). If nCPAP was not tolerated, or failed to correct breathing abnormalities during sleep, a second PSG(T) was performed, using a BIPAP PSV. Our study shows that nCPAP (mean 8.5 ± 2 0 cmH2O) was considered a satisfactory therapy in 81 patients (77%). Twenty four (23%) required BIPAP PSV (mean IPAP 13.9 ± 2.9 cmH2O). We found the highest prevalence of BIPAP in patients with OSAS associated to obesity hypoventilation syndrome (OHS) (11 of 17) and in OSAS associated to chronic obstructive pulmonary disease (COPD) (nine of 16). Patients treated with BIPAP PSV were more obese and had a higher PaCO2, and sleep-related desaturations and a lower FEV1, FVC, FEV1/FVC and PaO2. In conclusion our study shows that CPAP therapy is the effective therapeutic option in the majority of patients with OSAS, There is a subset of patients with OSAS associated to COPD or to OHS in whom BIPAP PSV may be a better treatment modality.

UR - http://www.scopus.com/inward/record.url?scp=0031827586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031827586&partnerID=8YFLogxK

U2 - 10.1016/S0954-6111(98)90383-3

DO - 10.1016/S0954-6111(98)90383-3

M3 - Article

C2 - 9850365

AN - SCOPUS:0031827586

VL - 92

SP - 820

EP - 827

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 6

ER -